Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Descending) Status
71288-0137-20 71288-0137 MITOMYCIN MITOMYCIN 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Sept. 8, 2022 In Use
71288-0138-50 71288-0138 MITOMYCIN MITOMYCIN 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Sept. 8, 2022 In Use
71288-0139-51 71288-0139 MITOMYCIN MITOMYCIN 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Sept. 6, 2022 In Use
71921-0178-20 71921-0178 Abiraterone acetate Abiraterone acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Aug. 15, 2022 In Use
72143-0252-30 72143-0252 ISOTRETINOIN ACCUTANE 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 1, 2022 In Use
72143-0253-30 72143-0253 ISOTRETINOIN ACCUTANE 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 1, 2022 In Use
72143-0254-30 72143-0254 ISOTRETINOIN ACCUTANE 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 1, 2022 In Use
72189-0383-30 72189-0383 Dexamethasone Dexamethasone 0.75 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 19, 2022 In Use
72205-0183-01 72205-0183 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
72266-0243-01 72266-0243 Bortezomib Bortezomib 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug. 23, 2022 In Use
72266-0244-01 72266-0244 Bortezomib Bortezomib 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug. 23, 2022 In Use
72819-0185-09 72819-0185 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2022 In Use
72819-0186-03 72819-0186 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2022 In Use
72143-0251-30 72143-0251 ISOTRETINOIN ACCUTANE 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 1, 2022 In Use
76282-0697-48 76282-0697 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
76282-0698-48 76282-0698 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
76282-0699-47 76282-0699 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
76282-0701-48 76282-0701 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
80425-0068-01 80425-0068 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 15, 2022 In Use
00832-0086-00 00832-0086 Fluoxymesterone Androxy 10.0 mg/1 Hormonal Therapy Androgen Oral Oct. 21, 1983 In Use
51407-0181-12 51407-0181 Abiraterone Acetate Abiraterone Acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Jan. 16, 2019 In Use
62175-0710-32 62175-0710 Anastrozole Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Jan. 5, 2011 In Use
67457-0254-30 67457-0254 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 23, 2016 In Use
68001-0510-85 68001-0510 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug. 13, 2021 In Use
68788-7281-02 68788-7281 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 16, 2019 In Use

Found 10,000 results in 6 milliseconds — Export these results